Navigation Links
PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
Date:11/29/2007

FRANKLIN, Mass., Nov. 29 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC) today reported that it has discussed the results of its pilot safety study of the RenalGuard System(TM) and Therapy with the U.S. Food and Drug Administration. Based upon the positive safety data already collected in the pilot study and its discussions with FDA, PLC has stopped enrolling new patients in the pilot study and will submit a request to transition into a new pivotal trial protocol.

The pilot trial was originally designed as a safety study for up to 40 patients; PLC has successfully enrolled and treated 23 patients in the pilot study at five approved sites to date. The company concluded that finishing the total planned enrollment was now unnecessary based upon the initial review of safety data already obtained.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "We are very pleased with the successful early conclusion to our pilot safety trial. This enables us to move forward expeditiously with our planned pivotal trial for this innovative therapy. Our pivotal trial is expected to be a multi-center, randomized controlled study designed to demonstrate that RenalGuard is effective in reducing the incidence of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing cardiovascular imaging procedures. The results from this pivotal trial will be used to support the regulatory approval process needed to market RenalGuard as a CIN prevention device. We expect to enroll patients at up to 30 sites throughout the country in this trial."

He added, "With the number of cardiovascular imaging procedures expected to grow in the future and more patients being deemed at risk of CIN due to underlying health conditions, we believe the need for a product such as RenalGuard is more critical than ever in preventing this expensive and potentially life threatening condition."

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world's first TMR angina relief device cleared for commercial distribution by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare, and to obtain a CE Mark for European distribution.

The company has been conducting a pilot clinical safety study of its RenalGuard Therapy(TM) and RenalGuard System. RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys. This therapy is based on the theory that creating and maintaining a high urine output is beneficial to patients undergoing imaging procedures where contrast agents are used. The real-time measurement and matched fluid replacement design of the RenalGuard System is intended to ensure that a high urine flow is maintained before, during and after these procedures. This should allow the body to rapidly eliminate contrast, reducing its toxic effects. The RenalGuard System, with its matched fluid replacement capability, is intended to minimize the risk of over- or under-hydration.

Additional company information can be found at http://www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product, the clinical trials for that product may not be successful, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in our Report on Form 10-Q for the quarter ended September 30, 2007, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser, RenalGuard, RenalGuard Therapy and RenalGuard System are trademarks of PLC Systems Inc.

Contact: Mary T. Conway

Conway Communications

617-244-9682

mtconway@att.net


'/>"/>
SOURCE PLC Systems Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
2. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
5. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
8. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
9. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ... into a settlement agreement with the United States ... SEC,s investigation into possible violations of the Foreign ... the settlement agreement, SciClone has agreed to pay ... interest and a penalty.  This payment is in ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... In sleep, when the defenses of the day are at rest, ... with eating disorders is significant self-criticism, and consequently these patients experience this disease with ... maladaptive means for coping with this unease, but also leads to a reservoir of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... practical mobile kitchens, recently announced the debut of their latest mobile kitchen model, ... Kitchens provides organizations with modern, high-volume commercial kitchens for use anywhere in the ...
(Date:2/5/2016)... Moscow, Russia (PRWEB) , ... February 05, 2016 , ... ... update has a completely new user interface design and the developer has fixed known ... with those they want to on their phone while not consuming any of their ...
(Date:2/5/2016)... ... , ... –This week, Atascadero water heater company First Call Plumbing ... view the report, click here or see below. , There are ... and cons, the type chosen is almost entirely up to personal preference. However, tankless ...
(Date:2/5/2016)... ... ... tired of trying to cram belongings into spare space that just isn’t there, a self-storage ... before hastily spending money on a unit, take these tips into consideration. , Self-storage is ... often not told when utilizing these services are some tips on how to use the ...
Breaking Medicine News(10 mins):